Mallinckrodt/NIH OxiFirst Fetal Oximetry Trial Will Evaluate Cesarean Rates
This article was originally published in The Gray Sheet
Executive Summary
Results of an NIH-supported, postmarket study of Mallinckrodt's OxiFirst fetal oxygen saturation monitoring system, evaluating the associated cesarean section rate, are at least four years away, according to the National Institutes of Health.
You may also be interested in...
Nellcor OxiFirst Verdict Contingent On NIH FOX Trial Results, Panel Agrees
Upgraded software for Nellcor's OxiFirst N400 fetal pulse oximetry system will be included in NIH's Fetal Oximetry trial (FOX), as the company attempts to ward off adverse events associated with misuse of the device
Nellcor OxiFirst Verdict Contingent On NIH FOX Trial Results, Panel Agrees
Upgraded software for Nellcor's OxiFirst N400 fetal pulse oximetry system will be included in NIH's Fetal Oximetry trial (FOX), as the company attempts to ward off adverse events associated with misuse of the device
Mallinckrodt OxiFirst Fetal Oxygen Monitor To Be Sold By Specialized Reps
Mallinckrodt is planning to sell its OxiFirst fetal oxygen saturation monitoring system through a dedicated sales force covering the entire U.S. FDA approval of the device was announced May 15.